SRPT: SEC Form 10-Q filed by Sarepta Therapeutics Inc.
9M collaboration revenue $365.0M vs $175.5M; $325.0M recognized after Roche declined an option, plus $40.0M Japan milestone.
What this filing says
Sarepta's nine-month collaboration revenue rose to $365.0 million, driven mainly by $325.0 million recognized after Roche declined to exercise an option for certain program rights in February 2026. Deferred revenue fell sharply, from $527.3 million at year-end 2025 to $188.8 million at September 30, 2026, because that option revenue was released. Shareholders should note this revenue reflects a one-time accounting recognition tied to the Roche agreement rather than recurring sales.
Key figures
- Nine-month collaboration revenue 2026
- $365.0 million
- Nine-month collaboration revenue 2025
- $175.5 million
- Option revenue recognized after Roche declined
- $325.0 million
- Japan first commercial patient milestone
- $40.0 million
- Total deferred revenue at September 30, 2026
- $188.8 million
- Shares outstanding November 2, 2026
- 107,235,848 shares
Positive for shareholders
- Collaboration revenue for the nine months roughly doubled compared with the prior year period.
- Roche dosed the first commercial patient in Japan, triggering a $40.0 million milestone payment.
Negative for shareholders
- No collaboration revenue was recognized in the three months ended September 30, 2026, versus the nine-month total.
- Total deferred revenue dropped from $527.3 million to $188.8 million, meaning a large portion of previously deferred revenue has now been recognized.
Written by Quantisnow AI from this filing. Not financial advice.
Key terms
- Option:
- A right granted to Roche to acquire ex-U.S. rights to certain future Duchenne programs by paying a separate exercise fee.
- Deferred revenue:
- Cash or payments received for work not yet performed, recorded as a liability until earned.
- Material right:
- A contract right that gives a customer a benefit beyond the standard terms, which must be accounted for separately.
- Contract manufacturing revenue:
- Income earned by producing and supplying product batches to a partner under a supply agreement.
FAQ
What drove Sarepta's higher collaboration revenue in 2026?
The filing says the largest driver was $325.0 million recognized in February 2026 after Roche declined to exercise an option, plus a $40.0 million milestone from the first commercial patient dosed in Japan.
Why did Sarepta's deferred revenue decline?
Deferred revenue fell to $188.8 million from $527.3 million, with the filing stating the reduction reflects revenue recognized under the Roche Collaboration Agreement.
Is the Roche Supply Agreement finalized?
No, the filing says the Roche Supply Agreement is still being negotiated, and supply is currently agreed on a purchase order-by-purchase order basis.
Historical context for SRPT
Across the 27 sessions after earlier SRPT headlines, the stock closed higher 14 times and lower 13 times, with a median move of 2.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | SRPT | SPY |
|---|---|---|---|
| Oct 27, 2026 | Sarepta Therapeutics to Present at Upcoming Investor Conferences | +5.1% | +0.6% |
| Oct 22, 2026 | Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results | -2.0% | -1.2% |
| Oct 14, 2026 | Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting | +1.9% | -1.1% |
| Oct 1, 2026 | Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -3.6% | +0.2% |
| Sep 30, 2026 | Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne | -2.3% | -0.2% |
| Sep 25, 2026 | Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress | +1.5% | +0.5% |
Keep researching SRPT
- SRPT financial statementsRevenue, profit, cash flow and balance sheet from Sarepta Therapeutics Inc.'s SEC filings.
- What is Form 10-Q?The quarterly report US public companies file with the SEC for each of the first three fiscal quarters, with unaudited financial statements and MD&A.
- Form 10-K vs 10-QThe difference between a 10-K and a 10-Q: what each report contains, filing deadlines by company size, audited vs reviewed financials, and which sections to read first.
- SRPT insider tradesEvery buy and sale reported by Sarepta Therapeutics Inc. officers, directors and large holders.
- SRPT earnings historyPast Sarepta Therapeutics Inc. earnings releases, newest first.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Follow SRPT and get a push notification the moment its next story breaks.